NCT07206758View on ClinicalTrials.gov

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions

Immune Thrombocytopenia

Interventions

DRUG

SHR-2173 Injection

SHR-2173 injection treatment

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY